Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep 4;10(9):1071.
doi: 10.3390/antibiotics10091071.

Enhanced Antibacterial Potential of Amoxicillin against Helicobacter pylori Mediated by Lactobionic Acid Coated Zn-MOFs

Affiliations

Enhanced Antibacterial Potential of Amoxicillin against Helicobacter pylori Mediated by Lactobionic Acid Coated Zn-MOFs

Haseena et al. Antibiotics (Basel). .

Abstract

H. pylori (Helicobacter pylori) causes a common chronic infectious disease and infects around 4.4 billion people worldwide. H. pylori was classified as a member of the primary class of stomach cancer (stomach adenocarcinoma). Hence, this study was conducted to design a novel lactobionic acid (LBA)-coated Zn-MOFs to enhance bactericidal activity of Amoxicillin (AMX) against H. pylori. The synthesized Zn-MOFs were characterized by various techniques which included Dynamic Light Scattering (DLS), Fourier Transform Infrared (FT-IR) Spectroscopy, Powder X-ray diffraction, scanning electron microscope, and atomic force microscope. They were capable of encapsulating an increased amount of AMX and investigated for their efficacy to enhance the antibacterial potential of their loaded drug candidate. Interestingly, it was found that LBA-coated Zn-MOFs significantly reduced the IC50, MIC, and MBIC values of AMX against H. pylori. Morphological investigation of treated bacterial cells further authenticated the above results as LBA-coated Zn-MOFs-treated cells underwent complete distortion compared with non-coated AMX loaded Zn-MOFs. Based on the results of the study, it can be suggested that LBA-coated Zn-MOFs may be an effective alternate candidate to provide new perspective for the treatment of H. pylori infections.

Keywords: Amoxicillin; H. pylori; lactobionic acid; metal organic frameworks (MOFs).

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
FTIR Spectrum of ATA, Zn-Acetate, Zn-MOFs, AMX, Am-ZnMOFs, and L-Am-Zn-MOFs.
Figure 2
Figure 2
The UV spectrum of pure AMX showing the peak at 230 nm (a). UV spectrum of Zn-MOFs showing the peak at 326 nm (b). UV spectrum of AMX-loaded Zn-MOFs showed a slight variation in AMX peak (c). UV spectrum of AMX after its release from Zn-MOFs (d).
Figure 3
Figure 3
Representative AFM images showing size variation between Zn-MOFs (a) and LBA-coated Am-Zn-MOFs (b).
Figure 4
Figure 4
Powder X-ray diffraction pattern of Zn-MOFs.
Figure 5
Figure 5
AFM images of H. pylori control cells (a), H. pylori AMX treated (b), H. pylori Zn-MOF treated (c), H. pylori Am-Zn-MOF treated (d), and H. pylori L-Am-Zn-MOF treated (e).
Figure 6
Figure 6
H. pylori control cells (a), H. pylori AMX treated (b), H. pylori Zn-MOF treated (c), H. pylori Am-Zn-MOF treated (d), and H. pylori L-Am-Zn-MOF treated (e).

Similar articles

Cited by

References

    1. Wilson W. Prevention of infective endocarditis: Guidelines from the American heart association: A guideline from the American heart association rheumatic fever, endocarditis, and Kawasaki disease committee, council on cardiovascular disease in the young, and the council on clinical cardiology, council on cardiovascular surgery and anesthesia, and the quality of care and outcomes research interdisciplinary working group. Circulation. 2007;116:1736–1754. - PubMed
    1. Akhavan B.J., Khanna N.R., Vijhani P. Amoxicillin. StatPearls Publishing; San Francisco, CA, USA: 2020. - PubMed
    1. Drissi M. Antibiotic susceptibility and mechanisms of β-lactam resistance among clinical strains of Pseudomonas aeruginosa: First report in Algeria. Med. Mal. Infect. 2008;38:187–191. doi: 10.1016/j.medmal.2008.01.009. - DOI - PubMed
    1. Hooi J.K. Global prevalence of Helicobacter pylori infection: Systematic review and meta-analysis. J. Gastroenterol. 2017;153:420–429. doi: 10.1053/j.gastro.2017.04.022. - DOI - PubMed
    1. Hatakeyama M., Brzozowski T. Pathogenesis of Helicobacter pylori infection. Helicobacter. 2006;11:14–20. doi: 10.1111/j.1478-405X.2006.00424.x. - DOI - PubMed

LinkOut - more resources